Авторы

  • Ахатова С.А.
  • Ахатов Ш.Ш.

Ключевые слова:

лейкоз, TP53, MYC, c-MYC, молекулярно-генетические аномалии, цитогенетика, FISH, кариотипирование, острый миелоидный лейкоз, острый лимфобластный лейкоз, миелодиспластический синдром, прогноз, выживаемость, генетические маркеры, персонализированная терапия.

Библиографические ссылки

1. Barbosa K., Li S., Adams P.D., Deshpande A.J. The role of TP53 in acute myeloid leukemia: Challenges and opportunities // Genes Chromosomes Cancer. – 2019. – Vol. 58, № 12. – P. 875–888.

2. Deshpande S., Li W.F., Song J., Forsberg M., Cerchione C., Martinelli G., Konopleva M. TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches // Frontiers in Oncology. – 2026. – Vol. 16. – Article 1735418.

3. Duncavage E.J., DiNardo C.D., Maciejewski J.P. A clinical guide to TP53 mutations in myeloid neoplasms // Blood. – 2025. – Vol. 146, № 18. – P. 2157–2167.

4. Global Cancer Observatory (GLOBOCAN). Leukaemia: Estimated number of new cases in 2022, worldwide. – Lyon: International Agency for Research on Cancer (IARC), 2022.

5. Gonzalez D., Martinez P., Wade R., Hockley S., Oscier D., Matutes E., Dearden C.E., Richards S.M., Catovsky D., Morgan G.J. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial // Journal of Clinical Oncology. – 2011. – Vol. 29, № 16. – P. 2223–2229.

6. Grob T., Al Hinai A.S.A., Sanders M.A., Kavelaars F.G., Rijken M., Gradowska P.L. et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome // Blood. – 2022. – Vol. 139, № 15. – P. 2347–2354.

7. International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data // Lancet Oncology. – 2016. – Vol. 17, № 6. – P. 779–790.

8. Kim H.J., Choi E.J., Wang L. TP53 in MDS and AML: Biological and clinical advances // Cancer Letters. – 2024. – Vol. 588. – Article 216767.

2. Kongkiatkamon S., Takahashi K., Short N.J., Daver N. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches // Annals of Hematology. – 2024. – Vol. 103. – P. 1147–1161.

3. Montalban-Bravo G., Takahashi K., Patel K. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions // Cancer Discovery. – 2022. – Vol. 12, № 11. – P. 2516–2529.

4. Nguyen-Khac F. "Double-Hit" Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes // Frontiers in Oncology. – 2022. – Vol. 11. – Article 826245.

5. Ok C.Y., Patel K.P., Garcia-Manero G. TP53-mutated myeloid neoplasms: 2024 update on diagnosis, risk stratification and management // American Journal of Hematology. – 2025. – Vol. 100. – P. 456–472.

6. Petrich A.M., Nabhan C., Smith S.M. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches // Cancer. – 2014. – Vol. 120, № 24. – P. 3884–3895.

7. Stengel A., Kern W., Haferlach T., Meggendorfer M., Fasan A., Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases // Leukemia. – 2017. – Vol. 31. – P. 705–711.

8. Stengel A., Schnittger S., Weissmann S., Kuznia S., Kern W., Kohlmann A., Haferlach T., Haferlach C. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis // Blood. – 2014. – Vol. 124, № 2. – P. 251–258.

9. Welch J.S., Petti A.A., Miller C.A., Fronick C.C., O'Laughlin M., Fulton R.S. et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes // New England Journal of Medicine. – 2016. – Vol. 375. – P. 2023–2036.

10. Xu Y., Wang Y., Zhao J. TP53 in AML and MDS: The new (old) kid on the block // Best Practice & Research Clinical Haematology. – 2023. – Vol. 36. – Article 101055.

11. Zenz T., Eichhorst B., Busch R., Denzel T., Häbe S., Winkler D. et al. TP53 mutation and survival in chronic lymphocytic leukemia // Journal of Clinical Oncology. – 2010. – Vol. 28, № 29. – P. 4473–4479.

12. Мусашайхова Ш.М., Бобоев К.Т., Мусашайхов У.Х. Роль генетического маркера Pro72Arg в гене TP53 в патогенезе острого миелоидного лейкоза // Медицинский журнал Узбекистана. – 2024. (уточнить № выпуска и страницы)

13. Мусашайхова Ш.М., Бобоев К.Т., Мусашайхов У.Х. Частота распределения аллелей и генотипов полиморфного маркера онкосупрессора TP53 у больных острым миелоидным лейкозом в зависимости от возраста пациентов // Медицинский журнал Узбекистана. – 2024. (уточнить № выпуска и страницы)